Developing a membrane-proximal CD33-targeting CAR T cell
Journal for ImmunoTherapy of Cancer · 2024-05 · 12 (5) · e009013
DOI: 10.1136/jitc-2024-009013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 20.05.2024. Verfasst von Ruby Freeman und 18 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Sialic Acid Binding Ig-like Lectin 3, Immunotherapy, Adoptive. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Center for Cancer Research, MSK Tri-Institutional Therapeutics Discovery Institute.
Abstract (Originalsprache)
Background
CD33 is a tractable target in acute myeloid leukemia (AML) for chimeric antigen receptor (CAR) T cell therapy, but clinical success is lacking.
Methods
We developed 3P14HLh28Z, a novel CD33-directed CD28/CD3Z-based CAR T cell derived from a high-affinity binder obtained through membrane-proximal fragment immunization in humanized mice.
Results
We found that immunization exclusively with the membrane-proximal domain of CD33 is necessary for identification of membrane-proximal binders in humanized mice. Compared with clinically validated lintuzumab-based CAR T cells targeting distal CD33 epitopes, 3P14HLh28Z showed enhanced in vitro functionality as well as superior tumor control and increased overall survival in both low antigen density and clinically relevant patient-derived xenograft models. Increased activation and enhanced polyfunctionality led to enhanced efficacy.
Conclusions
Showing for the first time that a membrane-proximal CAR is superior to a membrane-distal one in the setting of CD33 targeting, our results demonstrate the rationale for targeting membrane-proximal epitopes with high-affinity binders. We also demonstrate the importance of optimizing CAR T cells for functionality in settings of both low antigen density and clinically relevant patient-derived models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA renier.brentjens@roswellpark.org.
ORCID-Profile: Sanam Shahid, Anthony F Daniyan
Förderung
- NCI NIH HHS
- Center for Cancer Research
- MSK Tri-Institutional Therapeutics Discovery Institute
- Geoffrey Beene Cancer Research Center
- Memorial Sloan Kettering Cancer Center Support Grant/Core Grant
Zitieren
APA
Freeman, R., Shahid, S., Khan, A. G., Mathew, S. C., Souness, S., Burns, E. R., Um, J. S., Tanaka, K., Cai, W., Yoo, S., Dunbar, A., Park, Y., McAvoy, D., Hosszu, K. K., Levine, R. L., Boelens, J. J., Lorenz, I. C., Brentjens, R. J., & Daniyan, A. F. (2024). Developing a membrane-proximal CD33-targeting CAR T cell. Journal for ImmunoTherapy of Cancer, 12(5), e009013. https://doi.org/10.1136/jitc-2024-009013
Vancouver
Freeman R, Shahid S, Khan AG, Mathew SC, Souness S, Burns ER, et al. Developing a membrane-proximal CD33-targeting CAR T cell. Journal for ImmunoTherapy of Cancer. 2024;12(5):e009013. doi:10.1136/jitc-2024-009013
BibTeX
@article{Freeman2024,
author = {Freeman, Ruby and Shahid, Sanam and Khan, Abdul G and Mathew, Serena C and Souness, Sydney and Burns, Erin R and Um, Jasmine S and Tanaka, Kento and Cai, Winson and Yoo, Sarah and Dunbar, Andrew and Park, Young and McAvoy, Devin and Hosszu, Kinga K and Levine, Ross L and Boelens, Jaap Jan and Lorenz, Ivo C and Brentjens, Renier J and Daniyan, Anthony F},
title = {Developing a membrane-proximal CD33-targeting CAR T cell},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {5},
pages = {e009013},
doi = {10.1136/jitc-2024-009013}
}
EUVIMED